Literature DB >> 34408350

Analysis of Morbidity, Mortality and Survival Pattern Following Surgery for Borderline Ovarian and Malignant Ovarian Tumour in Tertiary Care Centre.

Shanmugasundaram Gouthaman1, Snehalatha Kothari2, Jaya Vijayaraghavan2, Ravi Shankar Pitani3.   

Abstract

BACKGROUNDS: To analyse the morbidity, mortality and survival pattern following surgery for borderline ovarian and malignant ovarian tumours.
METHODS: The medical records of 57 consecutive patients with invasive and borderline epithelial ovarian cancer patients registered and operated in our tertiary centre between 2015 to 2017 were reviewed. Patients were followed up for a minimum of 18 months to maximum of 42 months at an interval of 3 months with CA125 values. Various prognostic factors were analysed. The data descriptive statistics of frequency and percentage analysis were used for categorical variables and mean and standard deviation were used for continuous variables.
RESULTS: The most common age group was 51 years and above with the majority (56.2%) of women belonging to postmenopausal age group (32/57). In our study, 30 out of 57 women (52.6%) had stage III disease, 17 women had stage I disease (29.8%) and 7 women had stage 2 disease (12.3%). Majority of the women had serous epithelial ovarian tumour (47 out of 57 patients), which contributed to 82.4%. Grade 1 and 2 morbidity was encountered in 8 patients. Six patients had wound infection (grade 1), and 2 patients required blood transfusions (grade 2). One patient had grade 3 morbidity requiring re-laparotomy. Borderline tumours and early-stage epithelial ovarian tumours had good prognosis, less morbidity and good survival. The overall median survival was 25 months.
CONCLUSIONS: With meticulous perioperative care, surgery for ovarian cancer in the primary and interval setting can be done with minimal morbidity and no postoperative mortality, especially in patients with co-morbidities. Grade is an important prognostic factor affecting the survival of patients with epithelial ovarian cancers undergoing surgery. Lymph node dissection helps achieve local control but may not improve the survival. © Federation of Obstetric & Gynecological Societies of India 2021.

Entities:  

Keywords:  Clavien–Dindo classification; Cytoreductive surgery; Grade; Malignant ovarian tumour; Morbidity

Year:  2021        PMID: 34408350      PMCID: PMC8310809          DOI: 10.1007/s13224-020-01425-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  17 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

2.  Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials.

Authors:  Andreas du Bois; Alexander Reuss; Philipp Harter; Eric Pujade-Lauraine; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

3.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review.

Authors:  Jeffrey D Seidman; Anna Yemelyanova; Jonathan A Cosin; Anthony Smith; Robert J Kurman
Journal:  Int J Gynecol Cancer       Date:  2012-03       Impact factor: 3.437

6.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

7.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer.

Authors:  Wei Wei; Ning Li; Yangchun Sun; Bin Li; Lily Xu; Lingying Wu
Journal:  Oncotarget       Date:  2017-04-04

10.  Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study.

Authors:  Anne Fia Grann; Reimar Wernich Thomsen; Jacob Bonde Jacobsen; Mette Nørgaard; Jan Blaakær; Mette Søgaard
Journal:  Clin Epidemiol       Date:  2013-11-01       Impact factor: 4.790

View more
  1 in total

1.  Fertility Sparing Surgery and Borderline Ovarian Tumours.

Authors:  Lorraine S Kasaven; Mehar Chawla; Benjamin P Jones; Maya Al-Memar; Nicolas Galazis; Yousra Ahmed-Salim; Mona El-Bahrawy; Stuart Lavery; Srdjan Saso; Joseph Yazbek
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.